Request for Proposal

Two scientists review brain scans of a radiotherapy patient.

Seed grants application open through Oct. 31 

Questions about applying? Book a session with our team.

Learn more about Arizona’s Bioscience Roadmap.

Who should apply

The Flinn Foundation seeks proposals from research teams with innovative solutions to well-defined and compelling clinical needs in the areas of devices, diagnostics, health-focused technology platforms or delivery processes, and therapeutics. Other clinically compelling innovations, particularly those within precision medicine, are welcome to reach out and confirm eligibility. Proposed projects should have reached a point where there is significant potential to turn bench results into viable products or services to benefit patients in Arizona and beyond.

The Flinn Foundation Translational Seed Grants Program supports teams that include both scientists and clinicians affiliated with Arizona-based research institutions and/or health-care systems.

Key dates

Sept. 3, 2025: Application opens
Sept. 8, 2025: Info session on Zoom (View Slides)
Sept. 22, 2025 (11 a.m.): Group office hours on Zoom
Oct. 6-10, 2025: 1:1 Office hours on Zoom (BOOK)
Oct. 20-24, 2025: 1:1 Office hours on Zoom (BOOK)
Oct. 31, 2025 (5 p.m.): Application deadline
March 2026: Awardees announced

Individual office hours are on a first-come, first-served basis. Please do not book more than one session so everyone has an opportunity to receive feedback. 

Requirements

Proposed projects for the Flinn Foundation Translational Seed Grants Program require a submission in our application portal, including: 

  • Letter of support from the vice president of research or their designee at the principal investigator’s institution;
  • 300-word project summary; and
  • Slide deck with required elements.

Eligibility

For a research team to qualify for the program, the principal investigator must:

  • Be employed by an Arizona-based, nonprofit academic- or medical-research institution or health system. 
  • Have, or be working with their institution on, an agreed path for licensing or ownership of the project’s IP. 
  • Agree to participate in grant programming provided by the Flinn Foundation. 

Previous Flinn Foundation grantees may apply as a principal investigator if all previous Flinn grants are closed.

Competitive research teams will have: 

  • A proposed product and/or process that addresses a clearly defined, compelling clinical need; 
  • A project team that blends multi-disciplinary skills (e.g., scientific, clinical, engineering, business, regulatory) to meet the proposal goals; and
  • An application that adheres to the requirements specified above, especially the format and required elements of the slide deck.  

Benefits

Beyond the $100,000 grant, the program provides:

  • Quarterly cohort workshops to enhance teams’ skillsets in product development and commercialization; 
  • Networking and connections with research and industry experts; 
  • Referrals to programs, resources, and product-development/product-launch experts; 
  • The opportunity to pitch for an additional $100,000 in follow-on funding at the end of the original granting period; and 
  • Membership during the grant period on Arizona’s Bioscience Roadmap Steering Committee. 

Program expectations

Expectations of Project Teams

Selected teams will report quarterly and regularly present their case to scientific and industry leaders. By the end of the grant period, successful teams will significantly de-risk their product/process, refine their design, and/or acquire critical validation data. They will secure or have a well-defined plan to secure new funding to carry their project forward to real-world impact. 

Ideally, prior to the start of the grant period, the PI should have IRB approval and a plan for addressing intellectual property issues with their institution, including ownership and licensing of technology. 

Expectations of the Institution

The PI’s home institution must provide a letter of support signed by the Vice President of Research or their designee. The institution should have worked with the PI to secure IP or be in the process of doing so, with a path to agreement on licensing or ownership of the IP. 

Use of funds

The PI’s home institution will administer the grant; up to 10% of funds are allowable for administrative or institutional fees (indirect costs). 

Grant funding can cover or offset expenditures such as: 

  • Program-related lab expenses (materials, support staff, analysis). 
  • Prototype development, testing, and validation. 
  • Animal-model tests. 
  • Publication of data. 
  • Development/refinement of business plan and customer discovery. 
  • Development of proposals for follow-on funding from Small Business Innovation Research funds, National Institutes of Health grants, angel investments, philanthropic funds, etc. 

The Flinn Foundation may permit other uses of funds if deemed appropriate in the context of program goals and the nature of the team’s research. Funds may not support salaries, benefits, or other compensation of the PI or co-PI(s), or be applied toward prior debt. 

Application evaluation

Proposals will be evaluated by independent review committees of academic and industry experts appointed by the Flinn Foundation. Constructive feedback will be offered to applicants. 

Contact

For more information about the program or application process, contact Joanna Yang Yowler, Ph.D., Flinn Foundation Program Manager, Translational Biosciences & Entrepreneurship. 

“This grant helped us pursue our passion: developing solutions for unmet needs of people with Type 1 diabetes. The award enabled us to test our ideas at the bedside, then at the bench—with the aim to translate them back soon.”

Sampathkumar Rangasamy, Ph.D., Principal Investigator
Translational Genomics Research Institute in partnership with Mayo Clinic: “An innovative application for diabetes personalized care“